MINERALYS THERAPEUTICS INC(NASDAQ:MLYS) stock News

MLYS Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Chartmill - Mentions: CYTK UTHR IONS PPBT ...

Here are the top movers in Tuesday's session.

4 days ago - By: Chartmill - Mentions: CYTK UTHR ASNS PPBT ...

Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session.

2 days ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

2 days ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

4 days ago - By: Yahoo Finance

Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak

4 days ago - By: Benzinga - Mentions: ALKS BRKR TRMD PSO ...

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

4 days ago - By: Benzinga - Mentions: BURU CARM GOOG LUD ...

Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket

4 days ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

4 days ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

5 days ago - By: Chartmill - Mentions: CYTK MNKD UTHR IONS ...

There are notable gap-ups and gap-downs in today's session.

5 days ago - By: Chartmill - Mentions: CYTK MNKD UTHR MOVE ...

Tuesday's pre-market session: top gainers and losers

8 days ago - By: Investor's Business Daily - Mentions: GS AZN

AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results

20 days ago - By: Zacks Investment Research

Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade

a month ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

2 months ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

2 months ago - By: Bloomberg

Mineralys’ Drug Significantly Cut Blood Pressure in Key Study

4 months ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

4 months ago - By: Zacks Investment Research

Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going

4 months ago - By: Zacks Investment Research

Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy

4 months ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

4 months ago - By: Mineralys Therapeutics, Inc.

MINERALYS THERAPEUTICS INC (MLYS) Stock News

MLYS Latest News, Press Relases and Analysis

Here are the top movers in Tuesday's session.

Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session.

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

There are notable gap-ups and gap-downs in today's session.

Tuesday's pre-market session: top gainers and losers

AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results

Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

Mineralys’ Drug Significantly Cut Blood Pressure in Key Study

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going

Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025